Phase I Clinical Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
Latest Information Update: 28 Apr 2022
At a glance
- Drugs Anti-PD-L1 antibody Dragonboat Biopharmaceutical (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Dragonboat Biopharmaceutical
Most Recent Events
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.
- 16 Apr 2019 New trial record